<table id="t2" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 2: Clinically Significant Drug Interactions with Alfentanil HCl Injection
</caption>
<col align="left" width="13.100%"></col>
<col align="left" width="86.900%"></col>
<tbody>
<tr>
<td align="left" colspan="2" stylecode="Toprule Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Inhibitors of CYP3A4 and CYP2D6</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">The concomitant use of Alfentanil HCl Injection and CYP3A4 inhibitors can increase the plasma concentration of alfentanil, resulting in increased or prolonged opioid effects. These effects could be more pronounced with concomitant use of Alfentanil HCl Injection and CYP2D6 and CYP3A4 inhibitors, particularly when an inhibitor is added after a stable dose of Alfentanil HCl Injection is achieved <content stylecode="italics">[see Warnings and Precautions (<linkhtml href="#s17">5.4</linkhtml>)].</content>
<br/>After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, the alfentanil plasma concentration will decrease <content stylecode="italics">[see Clinical Pharmacology (<linkhtml href="#s71">12.3</linkhtml>)]</content>, resulting in decreased opioid efficacy or a withdrawal syndrome in patients who had developed physical dependence to alfentanil.
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">If concomitant use is necessary, consider dosage reduction of Alfentanil HCl Injection until stable drug effects are achieved <content stylecode="italics">[see Dosage and Administration (<linkhtml href="#s6">2.2</linkhtml>)]</content>. Monitor patients for respiratory depression and sedation at frequent intervals.<br/>If a CYP3A4 inhibitor is discontinued, consider increasing the Alfentanil HCl Injection dosage until stable drug effects are achieved <content stylecode="italics">[see Dosage and Administration (<linkhtml href="#s6">2.2</linkhtml>)].</content> Monitor for signs of opioid withdrawal.
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Examples:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g. ketoconazole), protease inhibitors (e.g., ritonavir)
</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">CYP3A4 Inducers</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">The concomitant use of Alfentanil HCl Injection and CYP3A4 inducers can decrease the plasma concentration of alfentanil <content stylecode="italics">[see Clinical Pharmacology (<linkhtml href="#s71">12.3</linkhtml>)]</content>, resulting in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence to alfentanil <content stylecode="italics">[see Warnings and Precautions (5.13)].</content>
<br/>After stopping a CYP3A4 inducer, as the effects of the inducer decline, the alfentanil plasma concentration will increase <content stylecode="italics">[see Clinical Pharmacology (<linkhtml href="#s71">12.3</linkhtml>)],</content> which could increase or prolong both the therapeutic effects and adverse reactions, and may cause serious respiratory depression.
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">If concomitant use is necessary, consider increasing the Alfentanil HCl Injection dosage until stable drug effects are achieved <content stylecode="italics">[see Dosage and Administration (<linkhtml href="#s6">2.2</linkhtml>)].</content> Monitor for signs of opioid withdrawal. If a CYP3A4 inducer is discontinued, consider Alfentanil HCl Injection dosage reduction and monitor for signs of respiratory depression.
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Examples:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Rifampin,  carbamazepine, phenytoin
</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Benzodiazepines and Other Central Nervous System (CNS) Depressants</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Diazepam administered immediately prior to or in conjunction with high doses of Alfentanil HCl Injection may produce vasodilation and hypotension, and may result in delayed recovery. Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when Alfentanil HCl Injection is administered in combination with other CNS depressants such as barbiturates, tranquilizers, opioids, or inhalation general anesthetics. Postoperative respiratory depression may be enhanced or prolonged by these agents.
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Monitor patients receiving Alfentanil HCl Injection and benzodiazepines or other CNS depressants for hypotension patients and prolonged respiratory depression and sedation. In such cases of combined treatment, the dose of one or both agents should be reduced. Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following alfentanil induction. <content stylecode="italics">[see Warnings and Precautions (<linkhtml href="#s15">5.2</linkhtml>)].</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Examples:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Benzodiazepines and other sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol.
</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Serotonergic Drugs</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome <content stylecode="italics">[see Warnings and Precautions (<linkhtml href="#s20">5.7</linkhtml>)].</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment. Discontinue Alfentanil HCl Injection if serotonin syndrome is suspected.
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Examples:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).
</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Monoamine  Oxidase Inhibitors</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Severe and unpredictable potentiation of monoamine oxidase (MAO) inhibitors has been reported rarely with alfentanil. MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma) <content stylecode="italics">[see Warnings and Precautions (<linkhtml href="#s15">5.2</linkhtml>)]</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">When Alfentanil HCl Injection is administered to patients who have received MAO inhibitors within 14 days, monitor patients for hypertension and ensure ready availability of vasodilators and beta-blockers for the treatment of hypertension as needed.
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Examples:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">phenelzine, tranylcypromine, linezolid
</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">May reduce the analgesic effect of Alfentanil HCl Injection and/or precipitate withdrawal symptoms.
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Avoid concomitant use.
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Examples:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">butorphanol,  nalbuphine,  pentazocine,  buprenorphine
</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Muscle Relaxants</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Alfentanil may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Monitor patients for signs of respiratory depression that may be greater than otherwise expected and decrease the dosage of Alfentanil HCl Injection and/or the muscle relaxant as necessary.
</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Diuretics</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone.
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Monitor patients for signs of diminished diuresis and/or effects on blood pressure and increase the dosage of the diuretic as needed.
</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Anticholinergic  Drugs</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus.
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Monitor patients for signs of urinary retention or reduced gastric motility when Alfentanil HCl Injection is used concomitantly with anticholinergic drugs.
</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Cimetidine</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Cimetidine reduces the clearance of alfentanil, extending the duration of action.
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Use smaller alfentanil doses for prolonged administration and monitor closely for respiratory depression and other effects of alfentanil.
</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Nitrous oxide</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Nitrous oxide has been reported to produce cardiovascular depression when given with higher doses of Alfentanil HCl Injection.
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Monitor patients for signs of cardiovascular depression that may be greater than otherwise expected.
</td>
</tr>
</tbody>
</table>